Actively Recruiting
Randomized, Placebo-controlled, Double-blind Study of 2LHERP® in Orofacial Herpes Infections.
Led by Labo'Life · Updated on 2024-10-31
140
Participants Needed
6
Research Sites
368 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Herpes simplex virus (HSV) infection is very common, as most people will experience herpetic infection during their lifetime. The most common manifestation of HSV infection is sores which may appear at any age. No specific antiviral therapy is available to totally cure herpetic infections and today, there is no treatment that allows the definitive eradication of the virus. The 2LHERP® has been available for more than 20 years, and has received a marketing authorization in Belgium by the FAMHP. It is used as an immune regulator in the treatment of herpetic infections. Since 2LHERP® has been made available, clinical observational data collected on treated patients have shown the beneficial effect on the disappearance of herpetic recurrences. The purpose of this placebo-controlled trial is to evaluate the efficacy of 2LHERP® on the treatment of herpetic infections in adults.
CONDITIONS
Official Title
Randomized, Placebo-controlled, Double-blind Study of 2LHERP® in Orofacial Herpes Infections.
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Man or woman aged 16-80 years
- Having 6 or more episodes of orofacial herpes infections in the 12 months before joining the study
- Woman of childbearing age under effective contraception
- In a stable sexual relationship during the study period
- Able to understand and follow study requirements
- Signed the informed consent form
You will not qualify if you...
- Pregnant or breastfeeding women
- Receiving immunotherapy or micro-immunotherapy in the past 6 months
- Had suppressive antiviral therapy in the past month
- Intending to continue suppressive antiviral therapy
- Known lactose intolerance
- Participated in another clinical study in the past 3 months
- Not motivated for 12 months of follow-up or likely to travel/move before study ends
- Severe immunodeficiency requiring long-term treatment, chemotherapy, radiotherapy, or corticoid therapy
- Using listed homeopathic or phytotherapy treatments
- Using or addicted to recreational drugs
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 6 locations
1
Private Practice
Beerzel, Belgium, 1650
Actively Recruiting
2
Cabinet privé
Beuzet, Belgium, 5030
Actively Recruiting
3
Clinique Saint-Luc (Bouge)
Bouge, Belgium, 5004
Actively Recruiting
4
Private Practice
Linkebeek, Belgium, 1630
Actively Recruiting
5
Cabinet privé
Noirefontaine, Belgium, 6831
Actively Recruiting
6
Private Practice
Oisquercq, Belgium, 1480
Actively Recruiting
Research Team
L
Laura FERTE
CONTACT
C
Charlotte BOLLE
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here